English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Breast cancer is estimated to account for 31% new onset female cancers. Matrix metalloproteinases (MMPs) are extracellular zinc-dependent endopeptidases involved in the degradation and remodeling of extracellular matrix in physiological and pathological processes. In this study, we aimed to evaluate the use of matrix metalloproteinase-13 (MMP-13) as a potential tumor marker in breast cancer and we also aimed to investigate the role of infection as a cause of carcinogenesis by estimating the incidence of anti-cytomegalovirus IgG antibodies in breast cancer patients. Subjects and Methods: Serum CA15.3, anti-CMV IgG and MMP-13 were measured in 50 breast cancer female patients, 20 female patients with fibroadenoma of breast and 20 healthy age-matched female volunteers. Results: MMP-13 levels showed no significant difference between breast cancer patients and controls; on the other hand MMP-13 levels were significantly higher in fibroadenoma patients compared to controls. CA15.3 levels were significantly higher in breast cancer cases compared to both fibroadenoma and healthy controls. Conclusion: The results of this study show that MMP-13 level is highest among control group, while fibroadenoma group had the lowest MMP-13 level. CA15.3 is still the most useful serum tumor marker in patients with breast cancer.

Matrix Metalloproteinase-13 (MMP-13): A proposed Tumor Marker in Breast Carcinoma